GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says
“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.
You may also be interested in...
New US FDA Generics Director Praises Industry, Encourages Partnerships
Refuse-to-receive rates for ANDAs are down, suggesting sponsors better understand the standards for quality applications, Office of Generic Drugs Director Sally Choe says in first speech to industry.
Generic Industry Once Again Must Get To Know New US FDA Office Director
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
Will GDUFA III Curtail Priority Assessments?
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.